Boston Scientific
Boston Scientific Corporation, a leading global medical technology company, is headquartered in the United States. Founded in 1979, the company has established itself as a key player in the medical device industry, focusing on innovative solutions across various therapeutic areas, including cardiovascular, rhythm management, and urology. With a strong presence in North America, Europe, and Asia-Pacific, Boston Scientific is renowned for its advanced products and services, such as minimally invasive devices and cutting-edge imaging technologies. The company’s commitment to innovation is exemplified by its numerous milestones, including the development of the first drug-eluting stent. Recognised for its market leadership, Boston Scientific continues to push the boundaries of medical technology, enhancing patient outcomes and improving quality of life. Its dedication to research and development positions it as a trusted partner in healthcare worldwide.
DitchCarbon Score
How does Boston Scientific's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boston Scientific's score of 92 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boston Scientific's reported carbon emissions
In 2024, Boston Scientific reported total carbon emissions of approximately 1,743,000,000 kg CO2e, comprising 87,567,000 kg CO2e from Scope 1, 9,854,000 kg CO2e from Scope 2, and a significant 1,663,859,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming for carbon neutrality in its manufacturing and key distribution sites by 2030. This commitment includes a near-term target to reduce absolute Scope 1 and 2 GHG emissions by 46.2% from a 2019 baseline by 2030. Boston Scientific has achieved a notable 68% reduction in Scope 1 and 2 emissions since 2009. Additionally, the company is committed to reducing Scope 3 emissions by 55% per USD value added within the same timeframe. Long-term goals include a 97% reduction in Scope 1 and 2 emissions per USD value added, equivalent to a 90% absolute reduction by 2050, alongside a similar target for Scope 3 emissions. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Boston Scientific's commitment to sustainability and reducing its environmental impact across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boston Scientific is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
